COAG Stock Chart & Stats
$47.55
$0.08(0.17%)
―
--
Day’s Range― - ―
52-Week Range$23.00 - $52.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)636.44K
Market Cap
$2.22B
Enterprise Value$0.00
Total Cash (Recent Filing)$163.53M
Total Debt (Recent Filing)$1.06M
Price to Earnings (P/E)―
Beta-2.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,705,410
10 Day Avg. Volume288,731
30 Day Avg. Volume636,443
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-5.28
Price to Sales (P/S)0.00
P/FCF Ratio-15.17
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$50.00Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
COAG FAQ
What was Hemab Therapeutics Holdings, Inc.’s price range in the past 12 months?
Hemab Therapeutics Holdings, Inc. lowest stock price was $23.00 and its highest was $52.15 in the past 12 months.
What is Hemab Therapeutics Holdings, Inc.’s market cap?
Hemab Therapeutics Holdings, Inc.’s market cap is $2.22B.
When is Hemab Therapeutics Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hemab Therapeutics Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Hemab Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts Hemab Therapeutics Holdings, Inc.’s price is currently Undervalued.
Does Hemab Therapeutics Holdings, Inc. pay dividends?
Hemab Therapeutics Holdings, Inc. does not currently pay dividends.
What is Hemab Therapeutics Holdings, Inc.’s EPS estimate?
Hemab Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemab Therapeutics Holdings, Inc. have?
Hemab Therapeutics Holdings, Inc. has 46,705,410 shares outstanding.
What happened to Hemab Therapeutics Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemab Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in COAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hemab Therapeutics Holdings, Inc. Stock Smart Score
Company Description
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
COAG Stock 12 Month Forecast
Average Price Target
$50.00
Ownership Overview
25.75% Insiders
<0.01% Other Institutional Investors
72.32% Public Companies and
Individual Investors